Cord Blood Banking: What Parents Need to Know Before Paying for Hope

Over the past two decades, private cord blood banks have convinced millions of families to pay thousands of dollars to store stem cells collected from their newborns' umbilical cords. The promise? That one day, perhaps, those cells might save their child’s life.

It is an emotionally powerful argument, and because it rests on emotion, it is especially dangerous. After all, if there is even the slightest chance that a biological sample might one day cure a cancer, neurological disorder, or some still unknown or rare disease, who would not want that option?

But advertising and science are two different things. When families do not always know how to distinguish between them, some people exploit that confusion to make money.

As reported and investigated by The New York Times and The BMJ, many private cord blood banks routinely exaggerate both cord blood’s current medical value and future potential, often blurring the distinction between established therapies, early-stage research, and mere speculation.

That does not mean cord blood is useless. Quite the opposite. It simply means that we need to understand what it is useful for and when it is not. So, what is so special about it?

Cord Bloods’ Cans and Cannots

The blood that remains in the umbilical cord after birth contains hematopoietic stem cells. Found in peripheral blood and bone marrow, these immature cells can develop into any type of blood cell, including white blood cells, red blood cells, and platelets. Several medical benefits come from this plasticity.

For more than three decades, doctors have successfully used these cells in transplants to treat a range of conditions, including leukemia, lymphoma, sickle cell anemia, and severe immunodeficiencies. In these cases, the transplanted cells replace the patient’s blood-forming system, which has been damaged or destroyed by the underlying disease. These therapies are now well established.

Cord blood stem cells have an additional medical advantage: because they are biologically immature, they tolerate greater genetic differences between donor and recipient than bone marrow transplants do. Since transplant rejection is always a problem, this characteristic made cord blood an extremely attractive alternative for patients unable to find a compatible bone marrow donor.

Many specialists saw cord blood as an important alternative source of stem cells for transplants. But optimism is not always rewarded with success. Or at least, success that is not always overwhelming. As researchers improved techniques for obtaining stem cells directly from adult peripheral blood and developed more efficient methods for performing partially compatible bone marrow transplants, reliance on cord blood steadily declined.

Contrary to optimistic predictions and current aggressive marketing, since 2014, transplants using donors who share half of the genes related to immune compatibility (haploidentical donors - usually parents, children, or siblings ) have become more common than cord blood transplants. This is not bad news; it is a sign of medical progress, providing physicians with more and, in many cases, clinically superior alternatives, capable of providing larger quantities of stem cells and better therapeutic outcomes.

Despite the changing applied science, many advertisements still present cord blood as though it were the future of regenerative medicine, when in reality it is just one tool, and sometimes an inferior one, among many.

How Marketing Turns Statistics into Sales

Private bank marketing often uses statistics in ways that encourage misleading interpretations. Claims that cord blood can treat “over 80 diseases” or that one in every 217 people will need a stem cell transplant during their lifetime leave out essential information: most of these diseases are extremely rare, and the latter estimate refers to stem cell transplants from any source, not specifically cord blood.

The result is an exaggerated impression of the benefits of private storage, achieved not by spreading false information but by omitting its scientific context.

But perhaps the most intuitive sales argument is also one of the weakest. Advertisements often reassure parents by saying that their baby’s cord blood will always be a “100% match” for the child.

While biologically true, it does not necessarily translate into a clinical advantage. In diseases such as leukemia, for example, the patient’s stem cells may carry the predisposition that gave rise to the cancer, making it preferable to use cells from a healthy donor. In at least some cases, then, it is better to avoid using the patient’s cord blood.

If exaggerated marketing were merely a problem of persuasive advertising, the consequences would be limited to families spending more money than necessary. Unfortunately, unrealistic expectations can also spill over into medical practice, where the line separating legitimate research from commercial exploitation becomes dangerously thin, and clinical trials can be marketed as established treatments.

Experimental Does Not Mean Proven

Failing to understand this means failing to understand the role of clinical trials: they exist because scientists do not know whether a therapy works. A successful Phase II trial may eventually become routine medical practice, but many, if not most, never get that far.

That distinction tends to disappear from promotional material.

Take cerebral palsy, one of the cases most frequently cited by cord blood bank marketing. A clinical study conducted by researchers at Duke University found modest improvements in motor function among some children treated with cord blood infusions, generating understandable excitement in the scientific and patient community. Even so, the treatment remains experimental.

The researchers themselves faced an unexpected problem.

Dr. Joanne Kurtzberg, who led the research, reported that more than half of the families interested in participating in the study were ultimately excluded because the cord blood they had stored in private banks contained too few stem cells or showed microbial contamination, making the samples medically unusable. That detail rarely appears in advertisements. Unsurprisingly, quality does matter.

When Stored Stem Cells Aren't Usable

Recent investigations have also raised concerns about quality control in part of the private storage industry.

According to The New York Times, some parents discovered that their children’s cord blood had been contaminated with bacteria shortly after collection. Others learned that the number of viable stem cells was insufficient for a transplant. Inspections conducted by the Food and Drug Administration (FDA) have also documented failures at some facilities, including issues with sterility testing and storage procedures.

While not every private bank operates below acceptable standards, this reveals an uncomfortable reality: parents are buying a product whose quality they will have little chance of independently verifying until the day they need to use it, all the while paying “storage fees.”

Autism, Stem Cells’ Latest Gold Rush

The gap between scientific evidence and commercial promises widens further when stem cells are offered for conditions with virtually no demonstrated benefit. Autism is a striking example.

In recent years, clinics in different American states have begun offering cord blood-derived stem cell infusions for autistic children, often charging between $10,000 and $20,000 per treatment, according to The Guardian.

The marketing follows a familiar script.

Parents are presented with moving stories, dramatic testimonials, and references to ongoing scientific research. Faced with a neurodevelopmental condition for which there is no cure, it is perfectly understandable that many families feel they need to try any alternative that might offer some hope.

We should have empathy for everything these families go through, but emotion and evidence do not always point in the same direction.

The largest randomized, placebo-controlled clinical trial conducted so far found that cord blood infusions were safe and well tolerated. But there was no significant improvement in social communication, vocabulary, or autism symptoms from cord blood infusions for autistic children. In children without intellectual disability, there were some signs of improvement in communication, attention, and brain activity, particularly with donor-derived cord blood, but the findings were limited and inconclusive.

The FDA continues to warn that stem cell therapies offered outside properly regulated clinical trials are generally not approved and may expose patients to unnecessary risks.

This is not a condemnation of stem cell research. Quite the opposite. Scientists should continue carefully investigating whether these therapies may one day benefit certain neurological disorders.

But there is an enormous ethical difference between conducting rigorous clinical research and selling expensive treatments whose effectiveness remains unproven.

Do advertising campaigns and centers for “regenerative medicine” care about that?

What Parents Should Know Before Banking Cord Blood

For new and expectant parents, the decision to bank cord blood is often fraught with hope, fear, and uncertainty. The emotional pull of wanting to protect your child is powerful—and it is precisely that vulnerability that aggressive medical marketing targets. 

But the lesson is clear: emotional appeals and dramatic promises cannot substitute for evidence. While stem cell science continues to advance, families deserve honest, transparent information to make decisions based on facts, not just hope.